Ansa Biotechnologies, Inc.

A lot of gene synthesis companies say they can handle complexity. Only one guarantees it. Ansa Biotechnologies was built for exactly this moment — not as a pivot or an upgrade, but as a founding mission. While others are adapting to where biology is heading, we’ve been built for it from the start. As AI accelerates genetic design, the bottleneck has shifted from imagination to execution. Longer sequences. More complex constructs. Tighter timelines. Meeting this moment requires more than capacity. It requires a platform engineered from the ground up for fidelity, scale, and consistency across every order — not one retrofitted for it. That’s the difference between adapting to this moment in biology and being built for it. At Ansa, complex DNA synthesis isn’t a capability we added. It’s the reason we exist. And we back it with the industry’s only On-Time Guarantee — because when the science is this important, confidence and reliability aren’t optional. Discover the industry’s only On-Time Guarantee in gene synthesis: https://hubs.li/Q04hldb80 #genesynthesis #complexity #guaranteed #NoDelaysJustDNA

🧬 Codon optimization is one of the most widely used — and misunderstood — tools in synthetic biology. And in many cases, the biggest limitation isn’t biology… it’s manufacturability. In our new blog post, the team breaks down why traditional codon optimization can be so unpredictable, and how advances in DNA synthesis are opening the door to entirely new approaches. Key takeaways: • Codon optimization is about far more than codon frequency or CAI scores • Sequence complexity, GC content, repeats, and secondary structures can all impact expression • Many “optimization” tools are actually constrained by what can be synthesized reliably • New synthesis technologies may allow researchers to explore a much larger sequence design space — and train better AI/ML models in the process Read the full article here: https://hubs.li/Q04h8XcR0 #SyntheticBiology #GeneSynthesis #CodonOptimization #CellTherapy #GeneTherapy #ProteinEngineering 

🧬 From synthetic biologist to startup founder…to leading the scientific vision of a company pushing the boundaries of what’s possible in DNA synthesis. We loved seeing The Scientist spotlight the journey, mindset, and curiosity of our CSO and Co-Founder, Daniel Lin-Arlow, and explore how scientist-founders are helping shape the future of biotech. If you’re excited about the future of synthetic biology, programmable biology, and the people turning science fiction into real-world impact, this one’s worth the read 👇 Read the article here: https://hubs.li/Q04g_h8_0

We’re excited to be at the #ASGCT Annual Meeting this week! 🍸🔬 𝗧𝗼𝗻𝗶𝗴𝗵𝘁: 𝗖𝗼𝗰𝗸𝘁𝗮𝗶𝗹𝘀 & 𝗦𝗰𝗶𝗲𝗻𝗰𝗲 🍸🔬 Join Ansa Biotechnologies for an evening of science, networking, and conversation with leaders in vector engineering and DNA synthesis. 𝗙𝗲𝗮𝘁𝘂𝗿𝗲𝗱 𝗽𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻: “Maintaining barcode fidelity is essential for successful screening of pooled AAV libraries” Presented by Laura Pereira, PhD Associate Director, Vector Engineering Roche Innovation Center Philadelphia Plus: A short overview of Ansa technology from Dan Lin-Arlow, PhD Chief Scientific Officer, Ansa Biotechnologies 📅 Wednesday, May 13 ⏰ 7:00–8:30 PM 📍 Aloft Hotel — Mahoney Exchange Room 📍 403 D Street, Boston, MA 👉Reserve your spot here: https://ansabio.com/asgct/ And while you’re at ASGCT, 𝘀𝘁𝗼𝗽 𝗯𝘆 𝗕𝗼𝗼𝘁𝗵 #𝟭𝟰𝟱𝟱 𝘁𝗼 𝗺𝗲𝗲𝘁 𝗼𝘂𝗿 𝘁𝗲𝗮𝗺 and learn how Ansa is accelerating complex DNA synthesis for next-generation therapeutics. #GeneTherapy #CellTherapy #GeneSynthesis

Headed to #𝗔𝗦𝗚𝗖𝗧𝟮𝟬𝟮𝟲 in Boston? Join us for an evening of cocktails, conversation, and science 🍸🧬 We’re bringing together leaders to explore what it takes to move science further — from maintaining barcode fidelity in pooled AAV library screening to the latest advances in DNA synthesis technology. Featured presentation: Maintaining barcode fidelity is essential for successful screening of pooled AAV libraries Laura Pereira, Associate Director, Vector Engineering  Roche Innovation Center Philadelphia Plus, a short overview of Ansa technology from Dan Lin-Arlow, Chief Scientific Officer and Co-founder Ansa Biotechnologies 📍 Wednesday, May 13 🕖 7:00–8:30 PM 📍 Aloft Boston Hotel - Seaport District 👉Register Now: https://ansabio.com/asgct/ Space is limited! And don’t miss us in the ASGCT exhibit hall at Booth #1455. #ASGCT #SyntheticBiology #CellAndGeneTherapy 

We’ve been having a blast at #SynBioBeta 🚀 Teaming up with our partners at Integrated DNA Technologies, we’re showcasing what’s possible when innovation meets collaboration...right from the show floor. From 100 bp to 50 kb, we’re delivering complex DNA to help power the next wave of discovery. If you’re here, come find us! We’re exhibiting side by side and would love to connect at booths #308 and #314. Daniel Lin-Arlow Tyler Miyawaki, PhD, MBA SynBioBeta

🧬 How far can your DNA take you? For most teams, the answer is still constrained by what can actually be built. At Ansa Biotechnologies, we’ve removed that limitation. We deliver complex, sequence-verified DNA from 100 bp to 50 kb. So you can design to the needs of biology, not the constraints of your typical DNA provider. That means no redesigning around: • High GC • Hairpins • Repeats 𝗚𝘂𝗮𝗿𝗮𝗻𝘁𝗲𝗲𝗱. We’re the only provider confident enough to stand behind delivery: if your order doesn’t ship on or before the stated date, it’s free. Bring us your most complex sequences and see how far your DNA can really take you. 👉Check us out: www.ansabio.com #SynBioBeta #GeneSynthesis #NoDelaysJustDNA 

🚀 We’re live at the Global Synthetic Biology Conference! 𝗧𝗵𝗶𝘀 𝘄𝗲𝗲𝗸, 𝗔𝗻𝘀𝗮 𝗕𝗶𝗼𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝗶𝗲𝘀 𝗶𝘀 𝘁𝗮𝗸𝗶𝗻𝗴 𝘁𝗵𝗲 𝘀𝘁𝗮𝗴𝗲 𝘁𝗼 𝘁𝗮𝗹𝗸 𝗮𝗯𝗼𝘂𝘁 𝘄𝗵𝗮𝘁 𝗵𝗮𝗽𝗽𝗲𝗻𝘀 𝘄𝗵𝗲𝗻 𝗗𝗡𝗔 𝗰𝗼𝗺𝗽𝗹𝗲𝘅𝗶𝘁𝘆 𝗶𝘀 𝗻𝗼 𝗹𝗼𝗻𝗴𝗲𝗿 𝘁𝗵𝗲 𝗯𝗼𝘁𝘁𝗹𝗲𝗻𝗲𝗰𝗸. Here’s where you can find us: 🎤 Tuesday | Main Stage Up and to the Right: A New Era of Innovation Enabled by AI and Complex DNA 🕑 2:15–2:25 PM Speaker: Jason T. Gammack   🎤 Tuesday | Industry Panel Breaking the Barriers of DNA Synthesis: Shattering the Ceiling 🕒 3:30–4:15 PM Panelist: Jason T. Gammack   🎤 Wednesday | Main Stage The New Biosecurity Frontier: AI, Automation, and the Rise of Biodefense 🕑 2:00–2:30 PM Panelist: Scott Fay   🧬 Wednesday | Breakout Session Skip the Assembly, Go Straight to Your Next Breakthrough 🕞 3:30–4:15 PM Featuring voices from across the synthetic biology ecosystem including Integrated DNA Technologies, Gilead Sciences, and Hexagon Bio. Moderator: Geoff Hamilton   📍 𝗩𝗶𝘀𝗶𝘁 𝘂𝘀 𝗮𝘁 𝗕𝗼𝗼𝘁𝗵 #𝟯𝟭𝟮 & 𝟯𝟭𝟰 If you’re working on sequences that others say are “too complex,” we should talk. #GeneSynthesis #SynBioBeta2026

“𝗧𝗵𝗲 𝗰𝗼𝗻𝘀𝘁𝗿𝗮𝗶𝗻𝘁𝘀 𝘄𝗲'𝘃𝗲 𝗯𝗲𝗲𝗻 𝘁𝗮𝘂𝗴𝗵𝘁 𝘁𝗼 𝗮𝗰𝗰𝗲𝗽𝘁 𝗮𝗿𝗲 𝗻𝗼𝘁 𝗹𝗮𝘄𝘀 𝗼𝗳 𝗻𝗮𝘁𝘂𝗿𝗲—𝘁𝗵𝗲𝘆'𝗿𝗲 𝗮𝗿𝘁𝗶𝗳𝗮𝗰𝘁𝘀 𝗼𝗳 𝗹𝗲𝗴𝗮𝗰𝘆 𝗺𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴.” That’s the perspective our CEO, Jason T. Gammack, is bringing into the SynBioBeta conference next week. In a recent feature article, he shares how Ansa is redefining DNA synthesis: • 50 kb sequence-perfect clonal DNA • <25 business day turnaround • 97%+ fulfillment on complex constructs • An On-Time Guarantee—if we’re late, you don’t pay As AI expands what scientists can design, we believe it’s time to remove the limits on what can be built. 👉 Read the full article to learn more: https://lnkd.in/gtpqbW2h #SynBioBeta #SyntheticBiology #DNA #Innovation

On 𝗗𝗡𝗔 𝗗𝗮𝘆, it’s worth reflecting on how far biology has come... and what’s still holding it back. We’ve solved how to read DNA, and we’re rapidly learning how to design it, but we still struggle to build it. 𝘋𝘕𝘈 𝘴𝘺𝘯𝘵𝘩𝘦𝘴𝘪𝘴 𝘳𝘦𝘮𝘢𝘪𝘯𝘴 𝘰𝘯𝘦 𝘰𝘧 𝘵𝘩𝘦 𝘣𝘪𝘨𝘨𝘦𝘴𝘵 𝘣𝘰𝘵𝘵𝘭𝘦𝘯𝘦𝘤𝘬𝘴 𝘪𝘯 𝘮𝘰𝘥𝘦𝘳𝘯 𝘣𝘪𝘰𝘭𝘰𝘨𝘺. Even today, scientists routinely redesign sequences—not for biological reasons, but because they can’t be manufactured. As AI accelerates design, that mismatch is only getting bigger. The question isn’t what we can imagine anymore, it’s whether we can actually build it. Hear what Ansa CEO Jason T. Gammack has to say about the changing landscape of DNA synthesis: https://lnkd.in/evinFtxA